Overview

Glucagon-like Peptide-1 in Type 1 Diabetes

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Maryland, Baltimore

Treatments:

Glucagon
Glucagon-Like Peptide 1